南部非洲艾滋病毒临床医生协会关于在一线抗逆转录病毒治疗中使用多替格拉韦的指南。

IF 1.6 4区医学 Q4 INFECTIOUS DISEASES

Southern African Journal of Hiv Medicine Pub Date : 2018-10-17 eCollection Date: 2018-01-01 DOI:10.4102/sajhivmed.v19i1.917

Michelle A Moorhouse, Sergio Carmona, Natasha Davies, Sipho Dlamini, Cloete van Vuuren, Thandekile Manzini, Moeketsi Mathe, Yunus Moosa, Jennifer Nash, Jeremy Nel, Yoliswa Pakade, Joana Woods, Gert van Zyl, Francesca Conradie, Francois Venter, Graeme Meintjes

{"title":"南部非洲艾滋病毒临床医生协会关于在一线抗逆转录病毒治疗中使用多替格拉韦的指南。","authors":"Michelle A Moorhouse, Sergio Carmona, Natasha Davies, Sipho Dlamini, Cloete van Vuuren, Thandekile Manzini, Moeketsi Mathe, Yunus Moosa, Jennifer Nash, Jeremy Nel, Yoliswa Pakade, Joana Woods, Gert van Zyl, Francesca Conradie, Francois Venter, Graeme Meintjes","doi":"10.4102/sajhivmed.v19i1.917","DOIUrl":null,"url":null,"abstract":"In preliminary data from the Tsepamo study in Botswana, it was found that 0.94% (95% confidence interval [CI]: 0.37 – 2.4) of babies (4/426) born to women who were taking dolutegravir periconception had neural tube defects (NTDs), compared with 0.1% of babies (14/11 173) of women taking other antiretroviral drugs (ARVs) in the periconception period.1 No NTDs were observed in pregnancies where dolutegravir was initiated later in pregnancy. Further data from the Tsepamo study were presented at AIDS 2018: the updated number of NTDs with periconception dolutegravir exposure in the Tsepamo cohort is 4/596, 0.67% (95% CI: 0.26 to 1.7). The next formal analysis will occur after 31 March 2019 and will include women exposed to dolutegravir from conception before the recent change in guidance. Tsepamo plans to expand the number of study sites, increasing the coverage from 45% to 72% of births in Botswana with a projected denominator of over 1200 by March 2019.1","PeriodicalId":49489,"journal":{"name":"Southern African Journal of Hiv Medicine","volume":"19 1","pages":"917"},"PeriodicalIF":1.6000,"publicationDate":"2018-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6244149/pdf/","citationCount":"6","resultStr":"{\"title\":\"Southern African HIV Clinicians Society Guidance on the use of dolutegravir in first-line antiretroviral therapy.\",\"authors\":\"Michelle A Moorhouse, Sergio Carmona, Natasha Davies, Sipho Dlamini, Cloete van Vuuren, Thandekile Manzini, Moeketsi Mathe, Yunus Moosa, Jennifer Nash, Jeremy Nel, Yoliswa Pakade, Joana Woods, Gert van Zyl, Francesca Conradie, Francois Venter, Graeme Meintjes\",\"doi\":\"10.4102/sajhivmed.v19i1.917\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In preliminary data from the Tsepamo study in Botswana, it was found that 0.94% (95% confidence interval [CI]: 0.37 – 2.4) of babies (4/426) born to women who were taking dolutegravir periconception had neural tube defects (NTDs), compared with 0.1% of babies (14/11 173) of women taking other antiretroviral drugs (ARVs) in the periconception period.1 No NTDs were observed in pregnancies where dolutegravir was initiated later in pregnancy. Further data from the Tsepamo study were presented at AIDS 2018: the updated number of NTDs with periconception dolutegravir exposure in the Tsepamo cohort is 4/596, 0.67% (95% CI: 0.26 to 1.7). The next formal analysis will occur after 31 March 2019 and will include women exposed to dolutegravir from conception before the recent change in guidance. Tsepamo plans to expand the number of study sites, increasing the coverage from 45% to 72% of births in Botswana with a projected denominator of over 1200 by March 2019.1\",\"PeriodicalId\":49489,\"journal\":{\"name\":\"Southern African Journal of Hiv Medicine\",\"volume\":\"19 1\",\"pages\":\"917\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2018-10-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6244149/pdf/\",\"citationCount\":\"6\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Southern African Journal of Hiv Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.4102/sajhivmed.v19i1.917\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2018/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Southern African Journal of Hiv Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4102/sajhivmed.v19i1.917","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2018/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 6

摘要

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Southern African HIV Clinicians Society Guidance on the use of dolutegravir in first-line antiretroviral therapy.

In preliminary data from the Tsepamo study in Botswana, it was found that 0.94% (95% confidence interval [CI]: 0.37 – 2.4) of babies (4/426) born to women who were taking dolutegravir periconception had neural tube defects (NTDs), compared with 0.1% of babies (14/11 173) of women taking other antiretroviral drugs (ARVs) in the periconception period.1 No NTDs were observed in pregnancies where dolutegravir was initiated later in pregnancy. Further data from the Tsepamo study were presented at AIDS 2018: the updated number of NTDs with periconception dolutegravir exposure in the Tsepamo cohort is 4/596, 0.67% (95% CI: 0.26 to 1.7). The next formal analysis will occur after 31 March 2019 and will include women exposed to dolutegravir from conception before the recent change in guidance. Tsepamo plans to expand the number of study sites, increasing the coverage from 45% to 72% of births in Botswana with a projected denominator of over 1200 by March 2019.1

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Southern African Journal of Hiv Medicine 医学-病毒学

CiteScore

2.80

自引率

11.80%

发文量

审稿时长

>12 weeks

期刊介绍： The Southern African Journal of HIV Medicine is focused on HIV/AIDS treatment, prevention and related topics relevant to clinical and public health practice. The purpose of the journal is to disseminate original research results and to support high-level learning related to HIV Medicine. It publishes original research articles, editorials, case reports/case series, reviews of state-of-the-art clinical practice, and correspondence.